Biao Luo, PhD


Assistant Research Professor


Research Program

Education, Training & Credentials

Educational Background

  • PhD, Biological Chemistry and Molecular Pharmacology, Harvard University, Cambridge, Massachusetts, 1998
  • Diploma, Peking Union Medical College and Beijing University, Beijing, People's Republic of China, 1991

Honors & Awards

  • Leukemia & Lymphoma Society Postdoctoral Fellowship, 1999-2002
  • Merck Fellowship, 1991-1992
Research Profile

Research Program

Research Interests

Improve cancer treatment through the application of cancer genomics

The ultimate goal of our research is to improve cancer treatment through the application of cancer genomics. Current efforts focus on the genomic analyses of cancer to identify patient-specific alterations that are important for development, progression and treatment of cancer.

Lab Overview

Precision Medicine in Molecular Diagnostics Laboratory: Patient Care

The Molecular Diagnostics Laboratory is a CLIA-certified, CAP-accredited clinical laboratory. We employ a variety of technologies and clinical assays to accurately characterize the clinically relevant genomic alterations in tumors.  Powerful and sophisticated NextGen Sequencing (NGS) technology is implemented to comprehensively determine the genetic lesions that characterize tumors in patients. The genetic information of the tumor is used for the selection of targeted treatment from both approved therapies and experimental therapies in clinical trials. In addition, the genetic profiles of tumors can be used for diagnosis, prognosis and monitoring of cancer in appropriate situations. 

Precision Medicine in Molecular Diagnostics Laboratory: Clinical Research

As the comprehensive Clinical Molecular Diagnostics Laboratory at Fox Chase Cancer Center, we are actively involved in the development and implementation of clinical trials and other clinical research programs in the diagnosis and treatment of cancer. The close collaboration between the molecular diagnostics laboratory, our clinicians and our scientists enables the multidisciplinary teams to vigorously develop and evaluate the experimental approaches in the management of cancer patients.


Selected Publications

Arora S, Yan H, Cho I, Fan HY, Luo B, et al. Genetic Variants That Presdispose to DNA Double-strand Breaks in Lymphocytes from a Subset of Patients With Familial Colorectal Carcinomas. Gastroenterology. 2015; PubMed

Hu W, Kaminski R, Yang F, Zhang Y, Cosentino L, et al. RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. Proceedings of the National Academy of Sciences of the United States of America. 2014; 111(31):11461-6. PubMed [journal] PMID: 25049410, PMCID: PMC4128125

Boyd J, Luo B, Peri S, Wirchansky B, Hughes L, et al. Whole exome sequence analysis of serous borderline tumors of the ovary. Gynecologic oncology. 2013; 130(3):560-4. NIHMSID: NIHMS588941 PubMed PMCID: PMC4083840

Horman SR, Janas MM, Litterst C, Wang B, MacRae IJ, et al. Akt-mediated phosphorylation of argonaute 2 downregulates cleavage and upregulates translational repression of MicroRNA targets. Molecular cell. 2013; 50(3):356-67. NIHMSID: NIHMS459763 PubMed PMCID: PMC3654076

Roberts JL, Buckley RH, Luo B, Pei J, Lapidus A, et al. CD45-deficient severe combined immunodeficiency caused by uniparental disomy. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109(26):10456-61. PubMed PMCID: PMC3387083

Cheung HW, Du J, Boehm JS, He F, Weir BA, et al. Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers. Cancer discovery. 2011; 1(7):608-25. NIHMSID: NIHMS331587 PubMed PMCID: PMC3353720

Cheung HW, Cowley GS, Weir BA, Boehm JS, Rusin S, et al. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108(30):12372-7. PubMed [journal] PMID: 21746896, PMCID: PMC3145679

Smolen GA, Zhang J, Zubrowski MJ, Edelman EJ, Luo B, et al. A genome-wide RNAi screen identifies multiple RSK-dependent regulators of cell migration. Genes & development. 2010; 24(23):2654-65. PubMed PMCID: PMC2994039

Gohil VM, Nilsson R, Belcher-Timme CA, Luo B, Root DE, et al. Mitochondrial and nuclear genomic responses to loss of LRPPRC expression. The Journal of biological chemistry. 2010; 285(18):13742-7. PubMed PMCID: PMC2859537

Zhang Q, Gu J, Li L, Liu J, Luo B, et al. Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. Cancer cell. 2009; 16(5):413-24. NIHMSID: NIHMS158221 PubMed PMCID: PMC2788761